Longitudinal associations between amygdala reactivity and cannabis use in a large sample of adolescents.


Journal

Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 11 03 2020
accepted: 27 07 2020
pubmed: 11 8 2020
medline: 27 1 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

The amygdala is a key brain structure to study in relation to cannabis use as reflected by its high-density of cannabinoid receptors and functional reactivity to processes relevant to drug use. Previously, we identified a correlation between cannabis use in early adolescence and amygdala hyper-reactivity to angry faces (Spechler et al. 2015). Here, we leveraged the longitudinal aspect of the same dataset (the IMAGEN study) to determine (1) if amygdala hyper-reactivity predicts future cannabis use and (2) if amygdala reactivity is affected by prolonged cannabis exposure during adolescence. First, linear regressions predicted the level of cannabis use by age 19 using amygdala reactivity to angry faces measured at age 14 prior to cannabis exposure in a sample of 1119 participants. Next, we evaluated the time course of amygdala functional development from age 14 to 19 for angry face processing and how it might be associated with protracted cannabis use throughout this developmental window. We compared the sample from Spechler et al. 2015, the majority of whom escalated their use over the 5-year interval, to a matched sample of non-users. Right amygdala reactivity to angry faces significantly predicted cannabis use 5 years later in a dose-response fashion. Cannabis-naïve adolescents demonstrated the lowest levels of amygdala reactivity. No such predictive relationship was identified for alcohol or cigarette use. Next, follow-up analyses indicated a significant group-by-time interaction for the right amygdala. (1) Right amygdala hyper-reactivity is predictive of future cannabis use, and (2) protracted cannabis exposure during adolescence may alter the rate of neurotypical functional development.

Identifiants

pubmed: 32772145
doi: 10.1007/s00213-020-05624-7
pii: 10.1007/s00213-020-05624-7
pmc: PMC7572697
mid: NIHMS1619555
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3447-3458

Subventions

Organisme : NIMH NIH HHS
ID : K08 MH121654
Pays : United States
Organisme : MRF
ID : MRF_MRF-058-0004-RG-DESRI
Pays : United Kingdom
Organisme : European Union
ID : LSHM-CT- 2007-037286
Organisme : Medical Research Council
ID : MR/R00465X/1
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P20 GM103644
Pays : United States
Organisme : NIH HHS
ID : U54 EB020403
Pays : United States
Organisme : Medical Research Council
ID : MR/S020306/1
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : P20GM103644
Pays : United States
Organisme : MRF
ID : MRF_MRF-058-0009-RG-DESR-C0759
Pays : United Kingdom

Références

J Child Psychol Psychiatry. 2000 Jul;41(5):645-55
pubmed: 10946756
Soc Cogn Affect Neurosci. 2011 Jan;6(1):12-23
pubmed: 20194512
J Neurosci. 2008 Mar 5;28(10):2313-9
pubmed: 18322078
Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
pubmed: 10817843
Neuropsychopharmacology. 2007 Sep;32(9):2036-45
pubmed: 17287821
Drug Alcohol Depend. 2014 Mar 1;136:51-62
pubmed: 24434016
Drug Alcohol Depend. 2009 Nov 1;105(1-2):139-53
pubmed: 19656642
Neuroscience. 1997 Mar;77(2):299-318
pubmed: 9472392
Dev Cogn Neurosci. 2015 Dec;16:63-70
pubmed: 26347227
JAMA Psychiatry. 2019 Apr 1;76(4):426-434
pubmed: 30758486
Arch Gen Psychiatry. 2005 Mar;62(3):282-8
pubmed: 15753241
Front Hum Neurosci. 2012 Nov 01;6:292
pubmed: 23125828
Mol Psychiatry. 2010 Dec;15(12):1128-39
pubmed: 21102431
Brain Res Rev. 2008 Jun;58(1):57-70
pubmed: 18076995
Int J Epidemiol. 2017 Oct 1;46(5):1641-1650
pubmed: 28520946
Addiction. 2012 Jul;107(7):1221-33
pubmed: 22300456
Drug Alcohol Depend. 2016 Sep 01;166:109-15
pubmed: 27427415
PLoS One. 2013 Sep 10;8(9):e74145
pubmed: 24040190
Psychopharmacology (Berl). 2008 Mar;196(4):661-72
pubmed: 18058090
Cereb Cortex. 2006 Aug;16(8):1087-96
pubmed: 16221928
Dev Neuropsychol. 2011;36(4):408-28
pubmed: 21516541
Neuroimage Clin. 2013 Jan 1;2:637-645
pubmed: 23977455
J Cogn Neurosci. 2008 Sep;20(9):1565-82
pubmed: 18345988
Arch Gen Psychiatry. 2008 May;65(5):568-76
pubmed: 18458208
Addict Behav. 2007 Oct;32(10):2238-52
pubmed: 17478056
Eur J Neurosci. 2019 Aug;50(3):2346-2356
pubmed: 29889330
Behav Neurosci. 2019 Dec;133(6):569-585
pubmed: 31448928
Sci Rep. 2017 Nov 3;7(1):15025
pubmed: 29101333
Neuropsychopharmacology. 2010 Feb;35(3):764-74
pubmed: 19924114
Front Hum Neurosci. 2014 Jun 05;8:393
pubmed: 24926249
JAMA Psychiatry. 2019 Apr 1;76(4):353-354
pubmed: 30810720
Biol Psychiatry. 2001 Feb 15;49(4):309-16
pubmed: 11239901
J Adolesc Health. 1993 May;14(3):190-5
pubmed: 8323929
Am J Drug Alcohol Abuse. 2002 Nov;28(4):643-52
pubmed: 12492261
J Child Psychol Psychiatry. 2009 Oct;50(10):1209-17
pubmed: 19490305
Neuroimage. 2005 May 1;25(4):1325-35
pubmed: 15850749
Neuroimage. 2012 Feb 1;59(3):2142-54
pubmed: 22019881
J Psychiatr Res. 2008 Feb;42(3):230-9
pubmed: 17320907
J Neurosci. 2013 Mar 6;33(10):4584-93
pubmed: 23467374
Neuroimage. 2010 Apr 1;50(2):727-33
pubmed: 20045736
J Neurosci. 2001 Dec 1;21(23):9506-18
pubmed: 11717385

Auteurs

Philip A Spechler (PA)

Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, 05401, USA. philip.spechler@uvm.edu.
Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA. philip.spechler@uvm.edu.

Bader Chaarani (B)

Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, 05401, USA.
Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Catherine Orr (C)

Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Matthew D Albaugh (MD)

Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Nicholas R Fontaine (NR)

Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Stephen T Higgins (ST)

Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, 05401, USA.
Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Tobias Banaschewski (T)

Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Arun L W Bokde (ALW)

Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience, Trinity College Dublin, Dublin, Ireland.

Erin Burke Quinlan (EB)

Centre for Population Neuroscience and Stratified Medicine (PONS) and MRC-SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Sylvane Desrivières (S)

Centre for Population Neuroscience and Stratified Medicine (PONS) and MRC-SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Herta Flor (H)

Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany.

Antoine Grigis (A)

NeuroSpin, CEA, Université Paris-Saclay, F-91191, Gif-sur-Yvette, France.

Penny Gowland (P)

Sir Peter Mansfield Imaging Centre School of Physics and Astronomy, University of Nottingham, University Park, Nottingham, UK.

Andreas Heinz (A)

Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.

Bernd Ittermann (B)

Physikalisch-Technische Bundesanstalt (PTB), Braunschweig-Berlin, Germany.

Eric Artiges (E)

Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie", Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and Psychiatry Department 91G16, Orsay Hospital, Paris, France.

Marie-Laure Paillère Martinot (MP)

Institut National de la Santé et de la Recherche Médicale, INSERM U A10 "Trajectoires développementales en psychiatrie", Université Paris-Saclay, Ecole Normale supérieure Paris-Saclay, CNRS, Centre Borelli; and AP-HP.Sorbonne Université, Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France.

Frauke Nees (F)

Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Department of Cognitive and Clinical Neuroscience, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Dimitri Papadopoulos Orfanos (DP)

Department of Psychology, School of Social Sciences, University of Mannheim, Mannheim, Germany.

Tomáš Paus (T)

Bloorview Research Institute, Holland Bloorview Kids Rehabilitation Hospital and Departments of Psychology and Psychiatry, University of Toronto, Paris, France.

Luise Poustka (L)

Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075, Göttingen, Germany.

Sarah Hohmann (S)

Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Juliane H Fröhner (JH)

Department of Psychiatry and Neuroimaging Center, Technische Universität Dresden, Dresden, Germany.

Michael N Smolka (MN)

Department of Child and Adolescent Psychiatry and Psychotherapy, University Medical Centre Göttingen, von-Siebold-Str. 5, 37075, Göttingen, Germany.

Henrik Walter (H)

Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Charité, Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.

Robert Whelan (R)

School of Psychology and Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland.

Gunter Schumann (G)

Centre for Population Neuroscience and Stratified Medicine (PONS) and MRC-SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.

Hugh Garavan (H)

Vermont Center on Behavior and Health, University of Vermont, Burlington, VT, 05401, USA.
Department of Psychiatry, College of Medicine, University of Vermont, Burlington, VT, 05401, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH